Email updates

Keep up to date with the latest news and content from AACI and BioMed Central.

Open Access Review

Evaluating the Safety of Intranasal Steroids in the Treatment of Allergic Rhinitis

Ketan Sheth

Author Affiliations

Lafayette Allergy and Asthma Clinic, Lafayette, IN, USA; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Pharmacy, Purdue University, West Lafayette, IN, USA

Allergy, Asthma & Clinical Immunology 2008, 4:125-129  doi:10.1186/1710-1492-4-3-125

Published: 15 September 2008

Abstract

Given that intranasal corticosteroids (INCs) are widely considered first-line therapies for treatment of rhinitis, it is important for the clinician to be comfortable with the side-effect profile and be able to discuss potential safety concerns regarding these therapies. Among the safety concerns with the use of INCs are the potential for growth suppression both short and long term, the potential for hypothalamic-pituitary-adrenal axis suppression, ocular safety, and the use of INCs concomitantly with inhaled corticosteroids in asthma patients. As all clinicians are aware, each patient can have individual responses to both efficacy and safety; however, the data reviewed suggest that the benefits outweigh the potential risks. Understanding the potential concerns and the data behind these concerns should give clinicians the information to be able to discuss this with patients and parents to incorporate appropriate therapy for those with allergic rhinitis

Keywords:
allergic rhinitis; intranasal corticosteroids; safety; treatment